

Recommendations of the SEC (Renal) made in its 05th/24 meeting held on 06.06.2024 at CDSCO (HQ), New Delhi:

| S. No | File Name & Drug Name, Strength | Firm Name | Recommendations |
|---------------------|--|------------------|--|
| GCT Division | | | |
| 1. | CT/45/21 Online Submission (32523) Iptacopan (LNP023) | M/s. Novartis | The firm presented protocol amendment version 02 dated 22.01.2024 protocol No. CLNP023B12301. After detailed deliberation, the committee recommended for approval of protocol amendment as presented by the firm. |
| 2. | CT/06/22 Online Submission (32071) Ianalumab | M/s. Novartis | The firm presented protocol amendment version 03 dated 14.12.2023 protocol No. CVAY736K12301. After detailed deliberation, the committee recommended for approval of protocol amendment as presented by the firm. |